Skip to content

MET · METLIFE INC

26 filings

10-K

MET 10-K Annual Reports

METLIFE INC - 26 annual reports

Filing record · 2016–202610-K1110-Q328-K249

2025
METLIFE INC Annual Report, Year Ended Dec 31, 2025
MetLife's 2025 Form 10-K shows a company in the midst of a strategic pivot toward asset management and group benefits, with steady adjusted earnings but compressed GAAP net income. Net income available to common shareholders fell to $3.2 billion in 2025 from $4.2 billion in 2024, driven primarily by unfavorable market risk benefit remeasurement and derivative results, while adjusted earnings available to common shareholders rose 2.5% to $5.9 billion. Management's key operating metrics point to resilience: adjusted premiums, fees and other revenues grew 10% to $57.4 billion, led by pension risk transfer and U.K. longevity reinsurance growth in RIS, and Asia and Latin America contributed strongly to segment earnings. The filing also marks a structural change. Under the New Frontier strategy, MetLife reorganized into six segments, adding MetLife Investment Management as a reportable segment and folding MetLife Holdings into Corporate & Other, and it closed the roughly $885 million cash acquisition of PineBridge Investments on December 30, 2025. Capital return remained substantial, with about $4.4 billion returned to shareholders in 2025, a $2.1 billion repurchase authorization remaining, and free cash flow of $4.9 billion across all holding companies, equal to 82% of adjusted earnings. Management maintained its 2026 targets of 15%-17% adjusted ROE, double-digit adjusted EPS growth, and a $25 billion five-year free cash flow goal for 2025-2029. Risks investors should weigh include a 2025 effective tax rate of 27% (versus 21% in 2024), a $100 million Mexican value-added tax charge, the forthcoming VM-22 principle-based reserving requirement for non-variable annuities, sensitivity of earnings to interest rate scenarios, a $2.2 billion increase in long-term debt and subordinated debt, and a large and growing asbestos liability. Net investment income rose to $22.6 billion, and the company's insurer financial strength ratings remained in the AA- to A+ range across major agencies.
Feb 19, 2026
2024
METLIFE INC Annual Report, Year Ended Dec 31, 2024
MetLife (MET) reported a stronger 2024 versus 2023, with net income available to common shareholders of $4.2 billion (diluted EPS $5.94) compared with $1.4 billion a year earlier, driven mainly by favorable investment gains/losses, derivative results and market risk benefit remeasurement. Adjusted earnings available to common shareholders, the company's preferred management measure, rose to $5.8 billion from $5.5 billion, with Asia (up $339 million on a reported basis) and Group Benefits and RIS as the largest contributors. Total revenues increased to $71.0 billion from $66.9 billion, supported by higher net investment income ($21.3 billion) and premium growth in Group Benefits and Latin America. Management set higher medium-term targets under its New Frontier five-year strategy, raising the adjusted return on equity target to 15%-17% (from 13%-15%), targeting double-digit adjusted EPS growth in the near term, and lowering the direct expense ratio target. The company returned about $21 billion to shareholders from 2020 through 2024, repurchased $3.2 billion of stock in 2024, and expects roughly $25 billion of free cash flow over the next five years. Holding company liquid assets were $5.1 billion, above the stated $3.0-$4.0 billion target. Key risks include exposure to interest rate movements (the 10-year Treasury sensitivity table shows material swings in adjusted earnings), elevated Level 3 fair value assets, long-term care and variable annuity guarantee liabilities, asbestos-related litigation, a pending Malaysia sale that was called off, the pending PineBridge acquisition, and a sizable regulatory and litigation backdrop including the New York False Claims Act suit. Statutory capital remains well above regulatory thresholds, with the Statement-Based Combined RBC ratio above 360%.
Feb 21, 2025
2023
METLIFE INC Annual Report, Year Ended Dec 31, 2023
MetLife's FY2023 10-K shows a year of heavy portfolio and reserving adjustment. GAAP net income available to common shareholders fell to $1.4 billion from $5.1 billion in 2022, driven mainly by $2.8 billion of net investment losses (including impairments tied to a reinsurance transaction and the pending MetLife Malaysia sale) and a higher effective tax rate of 26%. Adjusted earnings available to common shareholders, the company's preferred management measure, declined more modestly to $5.5 billion from $5.8 billion, with adjusted earnings down $268 million on a reported basis, pressured by higher interest crediting rates and lower variable investment income, partly offset by volume growth and favorable mortality in Group Benefits. The balance sheet remains substantial: total assets of $687.6 billion, total equity of $30.3 billion, and a Statement-Based Combined RBC Ratio above 380% for principal U.S. insurance subsidiaries. Management reported $5.2 billion of holding company cash and liquid assets against a $3.0-3.0 billion to $4.0 billion target, and free cash flow of all holding companies of $3.6 billion, a 66% ratio to adjusted earnings. Shareholder returns continued, with $3.1 billion of share repurchases and $1.6 billion of common dividends paid in 2023, leaving $2.1 billion of authorization remaining at year-end. Key items for investors include the adoption of LDTI accounting (ASU 2018-12) effective January 1, 2023, which restated prior-period comparatives, the November 2023 risk transfer reinsurance of an in-force MetLife Holdings block to Global Atlantic, the Q4 2023 reorganization into six segments, and an ongoing asbestos reserve increase to $364 million. Management's 2024 outlook calls for a 13%-15% adjusted return on equity target and a 65%-75% free cash flow conversion ratio over the near term.
Feb 16, 2024
2022
METLIFE INC Annual Report, Year Ended Dec 31, 2022
MetLife (MET) closed 2022 with a sharp drop in GAAP earnings and equity, driven by market forces rather than operating deterioration. Net income available to common shareholders fell to $2.35 billion from $6.35 billion, and adjusted earnings available to common shareholders fell 30% to $5.5 billion. The main drags were lower private equity and hedge fund returns, higher interest credited expense, and higher corporate expenses. Net investment gains turned to a $1.26 billion loss, and net derivative losses reached $2.37 billion as long-term interest rates rose sharply. Underwriting was favorable, with COVID-19 claims declining, and the U.S. segment grew adjusted premiums by 32%, largely from pension risk transfer business in RIS. The balance sheet absorbed a steep rise in interest rates. Accumulated other comprehensive income swung to a $27.1 billion loss from a $10.9 billion gain, pulling total MetLife, Inc. stockholders' equity down to $27.0 billion from $67.5 billion. Management reports $5.4 billion of holding company liquid assets, above its $3.0 to $4.0 billion target, and a free cash flow to adjusted earnings ratio of 84%. Shareholder returns continued, with $3.3 billion of buybacks and $1.6 billion of common dividends, and $1.2 billion of authorization remaining. The most important forward-looking item is the January 1, 2023 adoption of LDTI (ASU 2018-12). Management expects a roughly $22.5 billion reduction to total equity as of the January 1, 2021 transition date, including about $17.5 billion through AOCI and about $5.0 billion through retained earnings. Management also raised its adjusted return on equity target to 13% to 15% and set a 12.6% direct expense ratio target, and it flags continuing risks from interest rates, LIBOR transition, the Japan and Chile pension reform environments, and the asbestos and unclaimed property litigation.
Feb 23, 2023
2021
METLIFE INC Annual Report, Year Ended Dec 31, 2021
MetLife's 2021 Form 10-K, filed February 18, 2022, reports a year of strong earnings recovery and capital return against a backdrop of COVID-19 underwriting pressure. Net income available to common shareholders rose to $6.35 billion ($7.31 diluted EPS) from $5.19 billion in 2020, and adjusted earnings available to common shareholders increased $2.3 billion to $7.95 billion. Drivers included higher private equity and real estate returns, growth in net investment income on a larger asset base, and lower interest credited expenses, partly offset by roughly $1.2 billion of unfavorable underwriting tied to COVID-19 mortality and dental claims. Reported net income was also helped by the $1.0 billion after-tax gain on the April 2021 sale of MetLife P&C, though divestitures reduced adjusted earnings by $322 million. Capital and liquidity remained strong. Holding company cash and liquid assets stood at $5.4 billion, above the company's $3.0-$4.0 billion target. MetLife repurchased $4.3 billion of common stock during 2021 and paid $1.6 billion in common dividends, and it reported a Statement-Based Combined RBC ratio above 360%. Free cash flow of all holding companies was $3.8 billion, equal to 48% of adjusted earnings available to common shareholders, below the prior year's 71%. Management targets a 65%-75% two-year average free cash flow conversion, a 12%-14% adjusted ROE, and roughly $20 billion of cumulative free cash flow over 2020-2024. Investors should weigh several risks. Mortality and underwriting pressure from the pandemic persisted, the Next Horizon strategy relies on continued portfolio returns, and the company faces interest-rate sensitivity in MetLife Holdings and Japan, along with legacy risks such as asbestos litigation (about 58,800 pending claims), variable annuity guarantees, and an ongoing ex-MetLife Holdings run-off. The company also disclosed previously identified material weaknesses tied to group annuity reserves and assumed variable annuity reserves, and it is subject to several regulatory and derivative-demand investigations.
Feb 18, 2022
2020
METLIFE INC Annual Report, Year Ended Dec 31, 2020
MetLife's 2020 Form 10-K (filed February 19, 2021) shows a company generating $67.8 billion in total revenues and $5.4 billion in net income attributable to MetLife, Inc. (net income available to common shareholders of $5.2 billion, down from $5.7 billion in 2019). The decline was driven primarily by lower investment yields, a higher effective tax rate on adjusted earnings, a larger annual actuarial assumption review charge ($378 million versus lower in 2019), and an unfavorable change in net investment gains (losses), partially offset by a favorable change in net derivative gains from falling long-term interest rates. Adjusted earnings available to common shareholders fell $144 million to $5.6 billion, while the company reported $4.5 billion of holding company liquid assets, above its $3.0–$4.0 billion target. The filing frames MetLife's strategy around its 'Next Horizon' pillars of Focus, Simplify and Differentiate. Key 2020 actions included the agreed sale of MetLife P&C to Farmers Group for $3.9 billion (expected to close in Q2 2021), completed sales of MetLife Russia (closing January 2021) and MetLife Seguros de Retiro, and the acquisitions of Versant Health ($1.8 billion) and PetFirst. Management guided to a 2020–2021 average free cash flow to adjusted earnings ratio of 65%–75% and roughly $20.0 billion of cumulative free cash flow over 2020–2024, while flagging that the 12%–14% adjusted ROE target could be missed in 2021 given COVID-19, low rates and private equity return assumptions. The main investor watch items are the persistent low-interest-rate environment (with the Federal Reserve expected to keep rates near zero through 2023), COVID-19 impacts on mortality and claims, Level 3 fixed maturity securities that rose 57% to $29.5 billion, the pending MetLife P&C exit, ongoing litigation tied to group annuity reserving and related material weaknesses disclosed in 2018, and the $3.0 billion share repurchase authorization announced in December 2020 with $2.8 billion remaining at year-end.
Feb 19, 2021
2019
METLIFE INC Annual Report, Year Ended Dec 31, 2019
MetLife's 2019 Form 10-K shows a company in transition under its 'Next Horizon' strategy, which pivots toward protection-oriented and fee-based businesses and emphasizes free cash flow. Net income attributable to MetLife rose to $5.9 billion in 2019 from $5.1 billion in 2018, and net income available to common shareholders was $5.7 billion ($6.06 diluted EPS). Adjusted earnings available to common shareholders rose $306 million to $5.8 billion, helped by roughly $539 million of notable tax-related benefits, partly offset by $332 million of unit cost initiative expenses and a $143 million after-tax unfavorable actuarial assumption review. The balance sheet strengthened materially, with total stockholders' equity of $66.1 billion (up from $52.7 billion), largely driven by a $13.1 billion swing in accumulated other comprehensive income as interest rates fell. Management guides to a 65% to 75% free cash flow to adjusted earnings ratio over 2020 to 2021, targets $20 billion of free cash flow over five years, and projects 12% to 14% adjusted ROE. Capital return remained significant, with $16.0 billion returned to shareholders from 2016 through 2019 and $985 million left on the buyback authorization. Key risks include a sustained low interest rate environment that compresses investment spreads and pressures DAC/VOBA amortization, long-term care and variable annuity guarantee exposures, litigation and regulatory matters (including group annuity reserve issues that led to material weaknesses disclosed in 2018 and shareholder suits), and holding company dependence on subsidiary dividends. The 10-K also flags the pending sale of MetLife Hong Kong, the acquisitions of PetFirst and Willing, and the upcoming COVID-19 pandemic risk noted in the filing's risk factors.
Feb 21, 2020
2018
METLIFE INC Annual Report, Year Ended Dec 31, 2018
MetLife's 2018 Form 10-K, filed February 22, 2019, shows a company with a $452.0 billion general account portfolio and leading positions across the U.S., Japan, Latin America, Asia, Europe and the Middle East. Net income attributable to MetLife rose to $5.1 billion in 2018 from $4.0 billion in 2017, and net income available to common shareholders reached $4.98 billion. Adjusted earnings available to common shareholders increased $1.2 billion to $5.5 billion, the company's preferred non-GAAP measure for segment performance. Much of the improvement reflects a favorable $1.4 billion swing in net derivative gains and higher net investment income, partly offset by a lower 2017 tax benefit, an unfavorable annual actuarial assumption review ($358 million charge), and higher interest credited expense. The filing also carries significant governance and control risk. MetLife disclosed material weaknesses as of December 31, 2017 in RIS group annuity reserves and in MetLife Holdings assumed variable annuity guarantee reserves, and reported that both had been remediated by year-end 2018. Several related matters remain open, including SEC investigations, a New York DFS consent order with a $19.75 million fine, class-action securities suits, shareholder derivative litigation, and stockholder demand letters. Management reports the company returned $5.7 billion to common shareholders in 2018 through dividends and buybacks, and it maintains an adjusted ROE target of 12% to 14% over the near term. Investors should weigh the strong earnings and capital return against the reserve-accounting issues, regulatory exposure, and sensitivity to low interest rates and derivative valuations. Results also depend on the company's free cash flow conversion, which management projects at 65% to 75% for 2019–2020.
Feb 22, 2019
2017
METLIFE INC Annual Report, Year Ended Dec 31, 2017
MetLife's 2017 10-K (filed March 1, 2018) shows a company in transition: total revenues rose to $62.3 billion and net income available to common shareholders improved to $3.9 billion from $747 million in 2016, helped largely by a $1.5 billion one-time benefit from U.S. Tax Reform and lower losses from discontinued operations. Adjusted earnings available to common shareholders increased modestly to $4.2 billion, and management pointed to the Separation of Brighthouse Financial as the key structural event, with the Brighthouse business now reported as discontinued operations and MetLife retaining a 19.2% stake. The most important issue for investors is the disclosure of material weaknesses in internal control over financial reporting. Deloitte issued an adverse opinion on internal control, tied to certain RIS group annuity reserves and assumed variable annuity guarantee reserves from a former Japan joint venture. MetLife revised prior results to reflect reserve adjustments: a $510 million increase in group annuity reserves and an $896 million decrease in assumed variable annuity guarantee reserves, with some amounts treated as errors. Regulators (NYDFS, SEC) are investigating, and the filing discloses a possible securities class action. The company's ability to remediate these weaknesses promptly is a key risk to monitor. On the capital side, MetLife returned substantial capital in 2017, repurchasing $2.9 billion of common stock and paying $1.7 billion in common dividends. Management outlined a 2018 plan to return about $5.0 billion to common shareholders, including the planned exchange of the retained Brighthouse shares, while the NAIC-based combined RBC ratio remained above 400%.
Mar 1, 2018
2016
METLIFE INC Annual Report, Year Ended Dec 31, 2016
MetLife's 2016 Form 10-K (filed March 1, 2017) reports a year of heavy charges and a major corporate restructuring. Consolidated net income available to common shareholders fell to $697 million ($0.63 per diluted share) from $5.15 billion ($4.57) in 2015, driven mainly by a $6.8 billion unfavorable swing in net derivative results, largely from an annual actuarial assumption review on U.S. variable annuity guarantees, plus a $260 million goodwill impairment at Brighthouse Financial and a $340 million after-tax re-segmentation charge. Operating earnings available to common shareholders declined to $5.09 billion from $5.48 billion, reflecting lower investment yields in a sustained low-rate environment and unfavorable underwriting. Total revenues were $63.5 billion and the balance sheet stood at $898.8 billion in total assets with $67.5 billion of total equity. The central strategic event is the proposed separation of Brighthouse Financial, a spin-off of at least 80.1% of Brighthouse common stock to MetLife shareholders, which MetLife says it is still pursuing subject to regulatory approvals, an IRS ruling and SEC effectiveness of the Form 10. Management expects 2017 operating earnings to face downward pressure from separation execution, with growth resuming in 2018, and projects that over 40% of operating earnings will come from outside the U.S. after the separation. Holding-company liquidity was strained by $2.3 billion of separation-related outflows in 2016, though management expects dividends of $3.3 to $3.8 billion from Brighthouse in 2017 and targets a free cash flow ratio of 65% to 75% for 2017 to 2018. Investors should also weigh ongoing regulatory risk. The FSOC's designation of MetLife as a non-bank systemically important financial institution was rescinded by a district court in March 2016, but the government's appeal was argued in October 2016 and remains pending. Re-designation could impose enhanced capital and dividend constraints. Combined NAIC-based RBC ratios declined to 465% from 537%, and the separation could trigger dividend-stopper provisions on preferred stock and junior subordinated debt if GAAP net income is zero or negative while stockholders' equity drops at least 10%.
Mar 1, 2017
2015
METLIFE INC Annual Report, Year Ended Dec 31, 2015
MetLife's 2015 Form 10-K reports a year of mixed results: income from continuing operations fell to $5.3 billion from $6.3 billion, and operating earnings available to common shareholders declined about 16% to $5.5 billion from $6.6 billion. The main drags were lower investment yields from the sustained low interest rate environment, a $557 million tax charge (plus $235 million after-tax interest charge) tied to uncertain tax positions on a U.K. subsidiary's foreign tax credits, less favorable underwriting in property & casualty, and an unfavorable annual assumption review. Sales grew in several product lines, including retail annuities and accident & health, but overall sales declined from 2014. The balance sheet remained large and liquid, with $495 billion of total investments and $878 billion of total assets, and the company reported strong statutory capital, with a NAIC-based combined RBC ratio of 537%. Management returned significant capital to shareholders in 2015 through $1.9 billion of share repurchases and $1.65 billion of common dividends, and repurchased or redeemed $1.5 billion of Series B preferred stock while issuing $1.5 billion of new Series C preferred stock. The most significant strategic development is the January 12, 2016 announcement of a plan to pursue the "Separation" of a substantial portion of the U.S. Retail segment, certain Corporate Benefit Funding businesses, and parts of Corporate & Other. Structural alternatives under evaluation include an IPO, spin-off, or sale, and the outcome remains uncertain. Rating agencies responded in January 2016 with rating actions on several subsidiaries, including S&P's downgrade of GALIC and MetLife USA. MetLife also remains designated as a non-bank SIFI and G-SII, and it continues to litigate the non-bank SIFI designation.
Feb 25, 2016
2014
METLIFE INC Annual Report, Year Ended Dec 31, 2014
MetLife, Inc. (MET) reported its FY2014 Form 10-K, filed February 27, 2015, showing a strong earnings rebound with net income attributable to MetLife of $6.3 billion (vs. $3.4 billion in 2013) and operating earnings available to common shareholders of $6.56 billion (up from $6.26 billion). The improvement was driven largely by a $4.6 billion favorable swing in net derivative gains (to $1.3 billion from a $3.2 billion loss), which is volatile and non-operating, while operating results improved more modestly on higher net investment income from portfolio growth, higher asset-based fees, and lower interest credited expense, partly offset by unfavorable mortality/morbidity and the impact of falling investment yields from the sustained low interest rate environment. The balance sheet expanded to $902 billion in total assets, with stockholders' equity rising to $72.1 billion, and the company's general account portfolio at $516.8 billion. Management is targeting a 12%-14% operating ROE (excluding AOCI) by 2016, but now expects the lower end of that range, citing reduced share repurchases, regulatory uncertainty around MetLife's designation as a non-bank systemically important financial institution (SIFI), low U.S. interest rates, and the stronger U.S. dollar's effect on foreign operations. The company repurchased $1.0 billion of stock in 2014, declared a 2014 common dividend of $1.33 per share (up from $1.01), and has begun 2015 buybacks of about $739 million through February 23, 2015. Key risks for investors include the non-bank SIFI designation (which MetLife is contesting in federal court), potential enhanced capital requirements from the Federal Reserve, ongoing reserve financing/captive reinsurance scrutiny by regulators, variable annuity guarantee exposures, the sustained low interest rate environment compressing investment margins, and European and emerging-market economic uncertainty.
Feb 27, 2015
2013
METLIFE INC Annual Report, Year Ended Dec 31, 2013
MetLife, Inc. (MET) reported 2013 GAAP net income available to common shareholders of $3.25 billion ($2.91 diluted EPS), up from $1.20 billion in 2012, which was depressed by a $1.9 billion non-cash goodwill impairment on its U.S. Retail annuities business. Total revenues were essentially flat at $68.2 billion, while operating earnings available to common shareholders rose 11% to $6.29 billion, driven by higher asset-based fees, portfolio growth and lower interest credited expense, partly offset by lower yields. Net derivative losses of $3.2 billion, driven by rising interest rates and currency moves, were the main drag on GAAP results. The balance sheet is large, with $885 billion in total assets and a $496.4 billion general account portfolio, 71% of which is fixed maturity securities. Stockholders' equity declined to $61.6 billion, mainly because accumulated other comprehensive income fell from $11.4 billion to $5.1 billion as interest rates rose. The company completed the ProVida acquisition in Chile, and it has announced plans to merge three U.S. life insurers and an offshore reinsurer (the Mergers), expected in Q4 2014. Key risks for investors include the possibility that MetLife is designated a non-bank systemically important financial institution (SIFI) by the FSOC, which could bring enhanced capital requirements and limits on dividends and buybacks; regulatory scrutiny of captive reinsurance; a sustained low interest rate environment; variable annuity guarantee exposure; and litigation, including asbestos and unclaimed property matters. The company targets a 12% to 14% operating return on common equity excluding AOCI by 2016, and the Board declared a $0.275 quarterly dividend.
Feb 27, 2014
2012
METLIFE INC Annual Report, Year Ended Dec 31, 2012
MetLife's 2012 Form 10-K (filed February 27, 2013) reports a year of mixed results: GAAP income from continuing operations fell to $1.3 billion from $6.4 billion in 2011, driven mainly by a $6.7 billion unfavorable swing in net derivative results (from a $4.8 billion gain to a $1.9 billion loss), a $1.9 billion pre-tax goodwill impairment on the U.S. Retail Annuities unit, and a $1.2 billion charge tied to a global review of DAC, reserves and intangibles. Net income available to common shareholders was $1.2 billion, or $1.12 per diluted share, versus $6.2 billion in 2011. Management's non-GAAP operating earnings measure rose about 21% to $5.8 billion, and operating earnings available to common shareholders reached $5.7 billion, up from $4.7 billion, reflecting higher investment results, asset-based fee growth and lower catastrophe losses. The company remains a very large institution, with $836.8 billion in total assets, a $533 billion general account portfolio, and roughly 90 million customers across the U.S., Japan, Latin America, Asia and EMEA. Shareholder equity rose to $64.5 billion, helped by a $5.3 billion increase in accumulated other comprehensive income. Management guided to 2013 operating earnings roughly flat with 2012 despite low interest rates, and targets an operating return on common equity at the low end of 12%-14% by 2016. The filing also highlights material risk areas for investors: persistent low interest rates that compress spreads and pressure legacy guarantees, variable annuity guarantee exposure, European sovereign stress, potential designation as a non-bank systemically important financial institution, pending regulatory and litigation matters (including unclaimed property and sales practices), and a dilutive common equity unit settlement in 2013-2014. The company de-registered as a bank holding company and is winding down MetLife Bank, and it agreed to acquire Chile's Provida.
Feb 27, 2013
2011
METLIFE INC Annual Report, Year Ended Dec 31, 2011
MetLife's 2011 Form 10-K (filed February 28, 2012) reports a year of strong earnings recovery, driven mainly by a $4.8 billion net derivative gain and the first full year of ALICO results. Net income attributable to MetLife, Inc. was $6.98 billion (vs. $2.79 billion in 2010), and net income available to common shareholders was $6.71 billion, or $6.29 diluted EPS. Operating earnings rose 38.6% to $5.48 billion, and operating earnings available to common shareholders rose 39.8% to $5.36 billion. Total revenues grew 34.4% to $70.3 billion, largely reflecting the ALICO acquisition completed November 1, 2010. The balance sheet expanded to $799.6 billion in total assets, and stockholders' equity rose to $59.8 billion. Management also disclosed a planned reorganization into three geographic regions, the sale of most of MetLife Bank's depository business, and an exit from forward residential mortgage origination, with additional charges of $90 million to $110 million after tax expected in 2012. A pending DAC accounting change (ASU 2010-26) is expected to reduce DAC by $3.1 billion to $3.6 billion and total equity by $2.1 billion to $2.4 billion when adopted in Q1 2012. Investors should also note the Federal Reserve did not approve the proposed 2011 capital actions under CCAR 2011, and that the company's exposure to European sovereign debt was reduced substantially during 2011. Key risks include interest-rate sensitivity of spread-based products and variable annuity guarantees, Japan currency and earthquake-related exposure, litigation (including asbestos and unclaimed property audits covering more than 30 U.S. jurisdictions), and regulatory uncertainty from Dodd-Frank and potential non-bank SIFI designation.
Feb 28, 2012
2010-A
METLIFE INC Annual Report (Amendment), Year Ended Dec 31, 2010
MetLife Inc.'s (MET) 2010 10-K filing, filed in early 2011, provides a detailed overview of its corporate governance, director profiles, and executive compensation structures. The company emphasizes a strong board of directors with diverse industry experience, including significant representation from financial services, government, and non-profit sectors. The filing highlights MetLife's commitment to robust corporate governance, including independent board leadership, detailed committee responsibilities (Audit, Compensation, Finance & Risk, Governance & Corporate Responsibility), and a clear risk oversight framework overseen by the Board and its committees. Key investor takeaways include the company's "pay for performance" compensation philosophy, which heavily emphasizes variable and stock-based compensation for executives to align interests with shareholders. MetLife completed a significant acquisition in 2010, transforming its global presence, and reported improved financial results, including increased revenue and operating earnings. The filing also details the extensive equity compensation plans, director compensation, and executive remuneration, demonstrating a structured approach to attracting, retaining, and motivating key talent while managing risks associated with compensation practices.
Mar 1, 2011
2010
METLIFE INC Annual Report, Year Ended Dec 31, 2010
MetLife, Inc. reported robust financial performance for the fiscal year ending December 31, 2010, marked by a significant increase in net income available to common shareholders, reaching $2.67 billion, a substantial improvement from a net loss of $2.37 billion in 2009. This turnaround was largely driven by a favorable $3 billion shift in net derivative gains and a $1.6 billion improvement in net investment gains, reflecting a recovery in capital markets and the company's strategic financial management. The acquisition of ALICO for $16.4 billion on November 1, 2010, was a key event, significantly expanding MetLife's global footprint and diversifying its product and geographic mix, particularly strengthening its presence in Japan and Latin America. The company's operational segments, including U.S. Business (Insurance Products, Retirement Products, Corporate Benefit Funding, Auto & Home) and International, demonstrated resilience. The U.S. Business showed stable performance, while the International segment, bolstered by the ALICO acquisition, is expected to contribute significantly to future earnings. MetLife's strong capital position and commitment to shareholder value are underscored by its compliance with regulatory capital requirements and continued dividend payments.
Feb 25, 2011
2009-A
METLIFE INC Annual Report (Amendment), Year Ended Dec 31, 2009
This filing is a Form 10-K/A (Amendment) from MetLife, Inc. (MET), filed November 22, 2010, that amends only Part I, Item 1 (Business) and Part II, Item 7 (MD&A) of the original 10-K for fiscal year 2009 (originally filed February 26, 2010). The sole purpose of the amendment is to delete disclosures and references to the company's credit ratings, on the view that they may not constitute issuer disclosure-related ratings information. The amendment is stated as of December 31, 2009 and does not reflect subsequent events. Financial statements, risk factors, and other items are not included, so this document does not restate results and should not be used on its own for investment decisions. Investors should refer to the original 10-K for complete financial data. For context from the amended sections, MetLife reported a 2009 loss from continuing operations of $2.3 billion (versus income of $3.5 billion in 2008), driven mainly by a $7.8 billion pre-tax net investment loss, largely from freestanding derivatives hedging variable annuity guarantees. Operating earnings available to common shareholders fell 12% to $2.4 billion. The company describes itself as operating with a $328 billion general account portfolio and about 70 million customers across the U.S., Latin America, Asia Pacific, and EMEI. Management expects roughly 6% top-line growth and earnings recovery in 2010, while noting that the 2009 results were affected by market volatility and that the company was in discussions to acquire AIG's American Life Insurance Company. The key takeaway for investors is that this amendment changes disclosure language around ratings rather than the company's financial condition. Its main significance is as a documented change in what MetLife discloses about its credit and financial strength ratings, a topic that matters for funding costs and collateral requirements.
Nov 22, 2010
2009
METLIFE INC Annual Report, Year Ended Dec 31, 2009
MetLife Inc.'s 2009 10-K filing highlights a year of resilience amidst challenging economic conditions. The company maintained its position as a leading global provider of insurance, employee benefits, and financial services, serving over 70 million customers worldwide. Despite a net loss attributable to common shareholders in 2009, driven by significant net investment losses, MetLife demonstrated strength in its core businesses and international operations. The company reorganized its U.S. business segments for clearer reporting and continued to focus on strategic objectives including brand building, customer base expansion, global growth, and operational efficiencies. Key areas of focus for investors include MetLife's diversified product portfolio, its global market presence, its distribution channels, and its management's commitment to financial strength and shareholder value enhancement.
Feb 26, 2010
2008
METLIFE INC Annual Report, Year Ended Dec 31, 2008
MetLife Inc. reported its 2008 annual results, a year significantly impacted by the global financial crisis. The company experienced a notable decrease in net income available to common shareholders, primarily due to increased losses from discontinued operations related to the split-off of Reinsurance Group of America (RGA). However, the company's core insurance segments demonstrated resilience, with premiums, fees, and other revenues increasing across Institutional and International segments, driven by business growth. Despite a decrease in net investment income, MetLife's robust derivative hedging strategies helped offset some of the losses on embedded derivatives associated with variable annuities, resulting in net investment gains for the year. Management anticipates continued financial market volatility in 2009, projecting mixed results across segments. Key challenges include lower fee income from separate account businesses and potential declines in retirement and savings product demand. MetLife is focusing on disciplined underwriting, pricing, hedging, and expense management to navigate the economic environment. The company also raised capital through common stock offerings in 2008 to strengthen its position.
Mar 2, 2009
2007
METLIFE INC Annual Report, Year Ended Dec 31, 2007
MetLife, Inc. reported solid performance for the fiscal year ending December 30, 2007, driven by growth in its Institutional and International segments. The company's strategies, including brand recognition and expanding distribution channels, are contributing to its market position. While the company experienced a decrease in net income available to common shareholders primarily due to a significant gain from discontinued operations in the prior year, its core insurance and financial services businesses demonstrated resilience. MetLife continues to focus on product innovation and market expansion, particularly in international operations, positioning itself for long-term shareholder value creation. Investors should note the company's ongoing efforts to enhance capital efficiency and capitalize on retirement income needs.
Feb 28, 2008
2006
METLIFE INC Annual Report, Year Ended Dec 31, 2006
MetLife's 2006 Form 10-K reports a strong year: net income available to common shareholders rose 32% to $6,159 million, and diluted EPS reached $7.99 versus $6.16 in 2005. Much of the jump is one-time: income from discontinued operations hit $3,188 million, driven mainly by a roughly $3.0 billion after-tax gain on the sale of Peter Cooper Village and Stuyvesant Town for $5.4 billion. Income from continuing operations was essentially flat at $3,105 million, and excluding Travelers and certain items it declined, with weaker interest margins, $1,350 million of net investment losses (largely derivative mark-to-market and FX), and higher expenses. The balance sheet grew to $527.7 billion in total assets, with stockholders' equity up to $33.8 billion and book value supported by retained earnings. The 2005 acquisition of Travelers (for $12.1 billion) remains a major driver of scale, adding goodwill of $4.9 billion and DAC/VOBA of $20.9 billion, and it is also the source of significant integration and financing costs. Management resumed share buybacks in Q4 2006 and authorized an additional $1 billion program in February 2007. Key risks for investors include interest rate sensitivity (spread compression in low-rate environments such as Taiwan), equity-market exposure on variable annuity guarantees, a large asbestos and sales-practices litigation overhang, and a 36.3% stake in the company's shares held by the MetLife Policyholder Trust, which gives the board substantial influence over stockholder votes. Also disclosed are upcoming accounting changes (SOP 05-1, FIN 48) expected to reduce retained earnings by several hundred million dollars in 2007.
Mar 1, 2007
2005
METLIFE INC Annual Report, Year Ended Dec 31, 2005
MetLife, Inc. (NYSE: MET) reported its FY2005 results in this 10-K, filed February 28, 2006, showing a transformational year defined by the $12.0 billion acquisition of Travelers (The Travelers Insurance Company, excluding Primerica, plus most of Citigroup's international insurance operations), which closed July 1, 2005. Net income available to common shareholders rose to $4,651 million (diluted EPS $6.16) from $2,758 million ($3.65) in 2004. Much of the jump was driven by discontinued operations, which contributed $1,575 million after the sales of One Madison Avenue and 200 Park Avenue real estate (a combined $1,193 million after-tax gain), SSRM, and MetLife Indonesia. Income from continuing operations grew 19% to $3,139 million, and Travelers contributed only $233 million of that after integration, financing, and reserve charges, so the underlying organic improvement was more modest. The balance sheet expanded sharply: total assets reached $481.6 billion (from $356.8 billion) and stockholders' equity rose to $29.1 billion, while long-term debt nearly doubled to $9.9 billion and the company issued preferred stock, common equity units, and senior notes to fund the deal. Goodwill rose to $4.8 billion, including $4.2 billion from Travelers, which creates future impairment risk if the acquired business underperforms. Ratings agencies placed many MetLife entities on negative outlook after the deal and leverage increased, which management says it expects to reduce over time through retained earnings. Key investor considerations are leverage and integration execution, interest rate sensitivity (fixed maturities are about 75% of invested assets and a 10% rate rise implies a roughly $5.6 billion non-trading fair value loss), and ongoing legal exposure, notably asbestos claims (about 100,250 pending), sales practices litigation, and industry-wide broker compensation investigations. The company also suspended its $1 billion share repurchase program after the acquisition and raised its 2005 common dividend to $0.52 per share.
Feb 28, 2006
2004
METLIFE INC Annual Report, Year Ended Dec 31, 2004
MetLife's 2004 Form 10-K shows a company that grew earnings sharply: net income rose 24% to $2.76 billion ($3.65 diluted EPS), with income from continuing operations up 43% to $2.71 billion. The improvement was driven by a $485 million after-tax swing in net investment gains (from a $582 million loss in 2003 to a $182 million gain), higher interest rate spreads of roughly $302 million after tax in Institutional and Individual, and continued top-line growth. Total revenues reached $39.0 billion, and premiums, fees and other revenues grew 8% to $26.4 billion. Total assets were $356.8 billion and stockholders' equity was $22.8 billion, up from $21.1 billion, with return on equity of 12.5%. The filing also flags several items investors should weigh. MetLife announced an $11.5 billion agreement on January 31, 2005 to acquire most of Citigroup's Travelers Life & Annuity and international insurance businesses, with about $1 to $3 billion paid in MetLife stock and the remainder in cash funded by cash, debt, mandatorily convertible securities and asset sales. Share repurchases have been suspended as a result. The company also sold SSRM Holdings for $328 million in January 2005, producing about $150 million of discontinued-operations income, and is marketing two New York properties and considering selling some or all of its roughly 52% stake in Reinsurance Group of America. Legal exposure is substantial and includes asbestos claims (about 108,000 pending), sales practices suits, demutualization litigation, broker commission investigations and SEC Wells Notices. Management says it believes adequate provisions have been made, but it acknowledges that an adverse outcome could be material to quarterly or annual results. Regulatory capital and liquidity appear adequate. Metropolitan Life's total adjusted capital exceeds RBC thresholds, and the holding company's bank holding company ratios are above well-capitalized minimums. Liquid assets were $136 billion at the insurance group level and $2.1 billion at the holding company. The holding company's 2004 dividend doubled to $0.46 per share.
Mar 7, 2005
2003
METLIFE INC Annual Report, Year Ended Dec 31, 2003
MetLife's FY2003 10-K shows a company that substantially improved profitability in 2003. Net income rose 38% to $2.217 billion from $1.605 billion, and diluted EPS reached $2.94 versus $2.20. Income from continuing operations increased 71% to $1.943 billion, helped by a sharp decline in net investment losses (down to $358 million from $751 million) and by growth in premiums, fees, and assets under management. Total revenues grew 8% to $35.8 billion, and assets under management reached $350.2 billion, up 17%. Individual annuity deposits rose 42% to $11.2 billion. Management expects 2004 net investment losses to be comparable to 2003 levels. Balance sheet strength improved as stockholders' equity rose to $21.1 billion from $17.4 billion, driven by earnings, the settlement of equity purchase contracts, and unrealized investment gains. Return on equity reached 13.1% versus 10.8%. The company also bought back less stock, reduced treasury share count, and raised its annual dividend to $0.23 from $0.21. Regulatory capital ratios at the bank holding company and MetLife Bank remained above well-capitalized thresholds. Key risks include asbestos claims (over 111,700 pending claims at year-end, with a recorded liability of $1.225 billion as of 2002 and updated through 2003), numerous sales-practices and race-conscious underwriting lawsuits, pending SEC investigations, and exposure to interest-rate and credit risk in a $167.8 billion fixed-maturity portfolio. Deloitte & Touche issued an unqualified opinion. Overall, investors gain a larger, more profitable insurer with improving earnings quality, though income remains sensitive to investment losses, interest-rate movements, litigation outcomes, and a declining career-agent force.
Mar 5, 2004
2002
METLIFE INC Annual Report, Year Ended Dec 31, 2002
MetLife's 2002 10-K shows a company in transition: net income rebounded to $1,605 million ($2.20 diluted EPS) from $473 million in 2001, though much of the improvement came from a $266 million net charge for asbestos claims, a $402 million increase in the asbestos liability, and the favorable effects of prior-year items. Income from continuing operations rose to $1,155 million from $387 million, while $450 million came from discontinued operations, mainly gains on the sale of real estate (which fell from $1,676 million to $229 million in held-for-sale carrying value). Total revenues grew 6% to $33.1 billion, driven by premium growth of 11% to $19.1 billion, with the Institutional and International segments (including the Hidalgo acquisition in Mexico) contributing most of the increase. Return on equity recovered to 10.8% from 3.2%, and total assets reached $277.4 billion. Balance sheet and liquidity positions warrant attention. Long-term debt increased to $4.4 billion and short-term debt to $1.2 billion, and the Holding Company's liquid assets fell to $1.3 billion from $3.0 billion. Investment-grade fixed maturities represented 91.5% of the general account's fixed maturity portfolio, and net unrealized gains on investments recovered to $2.3 billion. The company repurchased $471 million of stock and paid a $0.21 annual dividend. Management notes that the holding company depends on dividends from Metropolitan Life, which is subject to New York regulatory limits. Several litigation exposures remain significant, most notably asbestos claims (approximately 106,500 pending, up from 89,000) and a range of sales practices, demutualization, and race-conscious underwriting lawsuits. For investors, the key questions are whether the earnings recovery is sustainable given the asbestos reserve increase, the equity market's effect on separate account fees and deferred acquisition costs, and whether the company can keep its strong financial strength ratings (Moody's Aa2/A1, S&P AA/A+) while integrating recent acquisitions and funding growth with more debt.
Mar 19, 2003